George Pascal Haber, MD, PhD, serves as the Chief Executive Officer (CEO) of Cleveland Clinic Abu Dhabi, part of the M42 group. Dr. Haber leads a team of over 5,600 caregivers, focusing on strategic growth, innovation, and excellence in high-acuity care. His leadership is instrumental in aligning with Cleveland Clinic and M42’s shared mission to drive innovation and implement tech-enabled health solutions, transforming the traditional healthcare landscape. In addition to focusing on his role as CEO, Dr. Haber will continue to practice as a urologist specializing in robotic surgery.
Prior to his appointment as CEO of Cleveland Clinic Abu Dhabi, Dr. Haber served as Chairman of the Glickman Urologic and Kidney Institute at Cleveland Clinic in Ohio. In this role, he significantly expanded patient services, enhanced surgical outcomes, and maintained the institute’s status as one of the top-ranked urology centers globally.
In over two decades of experience within the Cleveland Clinic global network, Dr. Haber has cemented his reputation as a surgical innovator. He led his surgical teams in performing the first ever scar-free removal of a healthy kidney for transplant in Europe, the first large series of scar-free kidney and prostate surgery performed through the belly button, the first ever robotic kidney transplant in the UAE, and multiple firsts at Cleveland Clinic including first robotic intracorporeal urinary diversion, robotic autotransplant and robotic Level 3 IVC thrombectomy.
Dr. Haber’s academic contributions dovetail with his surgical innovations and reflect his strong commitment to medical research and education. He has authored over 250 peer-reviewed scientific articles and has served as a visiting professor in over a dozen countries. Under his leadership, Cleveland Clinic’s urology residency training program became the largest urology training program in the United States and maintained a #1 national ranking.
Dr. Haber completed his executive education at Wharton and Harvard Business Schools; his clinical fellowship in robotic urologic surgery at Cleveland Clinic; and his Master of Science in Surgical Oncology, PhD in Biotechnology, and medical training in France.
